Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI7183 low dose · 1 trial · 1 indication
Remission at Week 8 was defined as a total Mayo score 2 points or smaller, and with no individual subscore more than 1 point.
| Arm | Type | Description |
|---|---|---|
| MEDI7183 dose 1 | EXPERIMENTAL | Double blinded |
| MEDI7183 dose 2 | EXPERIMENTAL | Double blinded |
| MEDI7183 dose 3 | EXPERIMENTAL | Double blinded |
| Placebo | PLACEBO_COMPARATOR | Double blinded |
| Name | Type | Description |
|---|---|---|
| MEDI7183 low dose | DRUG | MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8 |
| MEDI7183 medium dose | DRUG | MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8 |
| MEDI7183 high dose | DRUG | MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8 |
| Matching Placebo | DRUG | Placebo will be administered by SC on Day 1, Week 2,4, and 8 |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a histopathology report * Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with rectosigmoidoscopy...
Top 20 of 23 competitors
MEDI7183 low dose is an investigational small molecule being studied for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MEDI7183 low dose is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN.
MEDI7183 low dose is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval for any indication.
MEDI7183 low dose has been studied in one completed Phase 2 clinical trial, identified as NCT01959165, which evaluated its safety and efficacy in Japanese patients with ulcerative colitis. The trial enrolled 44 participants.
MEDI7183 low dose is a specific dosage form of the investigational drug MEDI7183. The low dose designation refers to the particular dose level being evaluated in clinical studies for ulcerative colitis.